10/31/14 MDT 68.16 Medtronic Inc $MDT Hit a 52 wee
Post# of 99
Posted On: 11/02/2014 1:14:54 AM
10/31/14 MDT 68.16 Medtronic Inc $MDT Hit a 52 week high of 68.41 Closing the day 10/31/14 at 68.16 +0.73 +1.08% With a day low of 67.89 and a total volume of 8,663,399.
MDT Recent Posts: http://investorshangout.com/Medtronic-Inc-MDT-51763/
MDT Medtronic Inc Recent Headline News
Final Glance: Medical Devices companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 111.24 (+1.96), JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), BAX: 70.14 (+0.08)
Medtronic Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Fri Oct 31, 3:49PM CDT
Medtronic (NYSE:MDT) traded in a range yesterday that spanned from a low of $67.89 to a high of $68.41. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $67.47 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDT: 68.16 (+0.73)
SmarTrend Watching for Potential Pullback in Shares of Medtronic After 1.08% Gain
Comtex SmarTrend(R) - Fri Oct 31, 3:48PM CDT
Medtronic (NYSE:MDT) traded in a range yesterday that spanned from a low of $67.89 to a high of $68.41. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $67.47 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDT: 68.16 (+0.73)
Midday Glance: Medical Devices companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 111.24 (+1.96), JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), BAX: 70.14 (+0.08)
Early Glance: Medical Devices companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 111.24 (+1.96), JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), BAX: 70.14 (+0.08)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 43.59 (+0.10), MDT: 68.16 (+0.73), COV: 92.44 (+0.83), RMD: 52.22 (+0.11), HOLX: 26.19 (+0.27)
Global Continuous Glucose Monitoring Market 2014-2018: Emerging Artificial Pancreas Technology
M2 - Fri Oct 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zk3lqw/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring Market 2014-2018" report to their offering. The Global Continuous Glucose Monitoring market to grow at a CAGR of 14.74% over the period 2013-2018 Continuous glucose monitoring is the measurement of glucose levels at regular intervals from a diabetic patient. Continuous glucose monitoring systems allow to gain insight into the trends of glucose levels between fingersticks, resulting in improved glucose control. Continuous glucose monitoring system comprises of a glucose sensor that is placed subcutaneously to provide the reading of glucose levels in tissue fluid. A transmitter sends information about the glucose levels using radio waves from the sensor to a receiver display. Continuous glucose monitoring system also offers additional information about HbA1C levels and fructosamine levels. The report covers the present scenario and the growth prospects of the Global Continuous Glucose Monitoring market for the period 2014-2018. In terms of component, the Global Continuous Glucose Monitoring market is divided into three segments: Transmitters and Receivers, Glucose Sensors, and Insulin Pumps. One key trend emerging in the market is the use of artificial pancreas technology in continuous glucose monitoring systems. The artificial pancreas is a closed-loop insulin delivery system that mimics the functions of a healthy pancreas in the human body by continuously monitoring glucose levels and automatically adjusting insulin delivery with minimal or no patient interaction. According to the report, one of the main drivers in this market is the rise in the incidence of diabetes across the population worldwide. Diabetes is also a cause of co-morbidities such as heart disease, stroke, kidney disease, blindness, and other debilitating diseases. The demand for continuous glucose monitoring has increased as diabetics look for ways to gain control over their glucose levels and manage them better. Further, the report states that one of the major challenges in the market is the presence of alternative methods of glucose monitoring. Blood glucose meters, test strips, and lancets, which are widely used in glucose monitoring products, can pose a hindrance to the adoption and growth in the popularity of continuous glucose monitoring systems. Key Vendors - Abbott Laboratories - Dexcom - Medtronic Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zk...continuous
ABT: 43.59 (+0.10), MDT: 68.16 (+0.73)
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire
PR Newswire - Thu Oct 30, 8:15AM CDT
Today, Analysts Review released its research reports regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Shire PLC (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7560-100free.
JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), AMGN: 162.18 (+0.60)
EnteroMedics Names Brad Hancock Chief Commercial Officer
PR Newswire - Thu Oct 30, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Brad Hancock will join the Company as Chief Commercial Officer effective November 17, 2014. Mr. Hancock has more than 30 years of experience in the medical device field serving in senior commercial operations and executive roles for St. Jude Medical and Medtronic, among others.
ETRM: 1.34 (unch), MDT: 68.16 (+0.73)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 68.16 (+0.73), EXAC: 21.30 (-0.05), CRY: 10.26 (+0.19)
Medtronic Initiates Clinical Study on Latest Heart Valve - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 5:10PM CDT
Medtronic's (MDT) structural heart business expanded in the upper teens owing to exceptional performance delivered by its transcatheter valves.
ZLTQ: 25.64 (-1.01), MDT: 68.16 (+0.73), GWPH: 73.75 (+3.29), ABAX: 52.66 (+1.13)
United Therapeutics Falls on Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:02AM CDT
United Therapeutics Corporation (UTHR) incurred a third-quarter loss of 53 cents per share, missing the Zacks Consensus Estimate by a wide margin.
LCI: 56.72 (+0.83), MDT: 68.16 (+0.73), UTHR: 130.97 (+0.54), NVS: 92.69 (+0.74)
Medtronic initiates PERIGON study of investigational pericardial surgical aortic heart valve for patients with aortic stenosis
M2 - Wed Oct 29, 6:20AM CDT
Medical technology company Medtronic (NYSE:MDT) revealed on Tuesday the launch of the PERIGON Pivotal Trial to evaluate the investigational surgical aortic heart valve made from bovine pericardial (cow heart) tissue.
MDT: 68.16 (+0.73)
MDT Recent Posts: http://investorshangout.com/Medtronic-Inc-MDT-51763/
MDT Medtronic Inc Recent Headline News
Final Glance: Medical Devices companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 111.24 (+1.96), JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), BAX: 70.14 (+0.08)
Medtronic Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Fri Oct 31, 3:49PM CDT
Medtronic (NYSE:MDT) traded in a range yesterday that spanned from a low of $67.89 to a high of $68.41. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $67.47 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDT: 68.16 (+0.73)
SmarTrend Watching for Potential Pullback in Shares of Medtronic After 1.08% Gain
Comtex SmarTrend(R) - Fri Oct 31, 3:48PM CDT
Medtronic (NYSE:MDT) traded in a range yesterday that spanned from a low of $67.89 to a high of $68.41. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $67.47 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDT: 68.16 (+0.73)
Midday Glance: Medical Devices companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 111.24 (+1.96), JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), BAX: 70.14 (+0.08)
Early Glance: Medical Devices companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 111.24 (+1.96), JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), BAX: 70.14 (+0.08)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 43.59 (+0.10), MDT: 68.16 (+0.73), COV: 92.44 (+0.83), RMD: 52.22 (+0.11), HOLX: 26.19 (+0.27)
Global Continuous Glucose Monitoring Market 2014-2018: Emerging Artificial Pancreas Technology
M2 - Fri Oct 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zk3lqw/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring Market 2014-2018" report to their offering. The Global Continuous Glucose Monitoring market to grow at a CAGR of 14.74% over the period 2013-2018 Continuous glucose monitoring is the measurement of glucose levels at regular intervals from a diabetic patient. Continuous glucose monitoring systems allow to gain insight into the trends of glucose levels between fingersticks, resulting in improved glucose control. Continuous glucose monitoring system comprises of a glucose sensor that is placed subcutaneously to provide the reading of glucose levels in tissue fluid. A transmitter sends information about the glucose levels using radio waves from the sensor to a receiver display. Continuous glucose monitoring system also offers additional information about HbA1C levels and fructosamine levels. The report covers the present scenario and the growth prospects of the Global Continuous Glucose Monitoring market for the period 2014-2018. In terms of component, the Global Continuous Glucose Monitoring market is divided into three segments: Transmitters and Receivers, Glucose Sensors, and Insulin Pumps. One key trend emerging in the market is the use of artificial pancreas technology in continuous glucose monitoring systems. The artificial pancreas is a closed-loop insulin delivery system that mimics the functions of a healthy pancreas in the human body by continuously monitoring glucose levels and automatically adjusting insulin delivery with minimal or no patient interaction. According to the report, one of the main drivers in this market is the rise in the incidence of diabetes across the population worldwide. Diabetes is also a cause of co-morbidities such as heart disease, stroke, kidney disease, blindness, and other debilitating diseases. The demand for continuous glucose monitoring has increased as diabetics look for ways to gain control over their glucose levels and manage them better. Further, the report states that one of the major challenges in the market is the presence of alternative methods of glucose monitoring. Blood glucose meters, test strips, and lancets, which are widely used in glucose monitoring products, can pose a hindrance to the adoption and growth in the popularity of continuous glucose monitoring systems. Key Vendors - Abbott Laboratories - Dexcom - Medtronic Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zk...continuous
ABT: 43.59 (+0.10), MDT: 68.16 (+0.73)
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire
PR Newswire - Thu Oct 30, 8:15AM CDT
Today, Analysts Review released its research reports regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Shire PLC (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7560-100free.
JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), AMGN: 162.18 (+0.60)
EnteroMedics Names Brad Hancock Chief Commercial Officer
PR Newswire - Thu Oct 30, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Brad Hancock will join the Company as Chief Commercial Officer effective November 17, 2014. Mr. Hancock has more than 30 years of experience in the medical device field serving in senior commercial operations and executive roles for St. Jude Medical and Medtronic, among others.
ETRM: 1.34 (unch), MDT: 68.16 (+0.73)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 68.16 (+0.73), EXAC: 21.30 (-0.05), CRY: 10.26 (+0.19)
Medtronic Initiates Clinical Study on Latest Heart Valve - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 5:10PM CDT
Medtronic's (MDT) structural heart business expanded in the upper teens owing to exceptional performance delivered by its transcatheter valves.
ZLTQ: 25.64 (-1.01), MDT: 68.16 (+0.73), GWPH: 73.75 (+3.29), ABAX: 52.66 (+1.13)
United Therapeutics Falls on Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:02AM CDT
United Therapeutics Corporation (UTHR) incurred a third-quarter loss of 53 cents per share, missing the Zacks Consensus Estimate by a wide margin.
LCI: 56.72 (+0.83), MDT: 68.16 (+0.73), UTHR: 130.97 (+0.54), NVS: 92.69 (+0.74)
Medtronic initiates PERIGON study of investigational pericardial surgical aortic heart valve for patients with aortic stenosis
M2 - Wed Oct 29, 6:20AM CDT
Medical technology company Medtronic (NYSE:MDT) revealed on Tuesday the launch of the PERIGON Pivotal Trial to evaluate the investigational surgical aortic heart valve made from bovine pericardial (cow heart) tissue.
MDT: 68.16 (+0.73)
(0)
(0)Medtronic, Inc. (MDT) Stock Research Links
Scroll down for more posts ▼